Compare GSK plc (GSK) vs Kohl's Corporation (KSS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Kohl's Corporation — how do they compare? GSK plc trades at $52.75 (market cap $101.34B), while Kohl's Corporation trades at $17.59 (market cap $1.94B). The key difference: GSK plc is far larger — about 52.2× Kohl's Corporation's market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | KSS | |
|---|---|---|
Market Cap | $101.34B | $1.94B |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $24.71 |
52-Week Low | $36.20 | $9.39 |
Enterprise Value | $121.95B | $8.04B |
Dividend Yield | 3.49% | 2.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
Kohl's (KSS) trades at $17.62, up 7.31% in the past 24 hours, with a bullish technical signal from moving averages. The stock shows deep value with a P/E of 7.18 and P/B of 0.48, while recent earnings beats and a 10% jump in juniors sales (Zacks, 2026-06-30) signal early turnaround progress. Cash flow improved to $276M net in 2026 from -$49M in 2025, though revenue has declined from $19.4B in 2022 to $16.2B in 2025.
The outlook hinges on successful execution of Kohl's value-focused strategy and proprietary brand growth to reverse sales declines. Risks include intense retail competition and macroeconomic pressure on consumer spending. Analysts are mixed with a $16.75 consensus target below the current price, suggesting cautious optimism amid restructuring efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →
